Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001389052 | SCV001590257 | pathogenic | Ataxia-telangiectasia syndrome | 2020-03-08 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant has not been reported in the literature in individuals with ATM-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Glu1783Thrfs*9) in the ATM gene. It is expected to result in an absent or disrupted protein product. |
Center for Genomic Medicine, |
RCV003321836 | SCV004027240 | pathogenic | not provided | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003469751 | SCV004212142 | pathogenic | Familial cancer of breast | 2022-12-25 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV003469751 | SCV004933186 | pathogenic | Familial cancer of breast | 2024-01-25 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |